Brief Ibogaine Bibliography
^^^^^^^^^^^^^^^^^^^^^^^^^^^
1. Aceto MD, Bowman E, Harris LS, Dependence studies of new compounds in
the rhesus monkey, rat and mouse, NIDA Research Monograph, 95:607,
1990.
2. Aceto MD, Bowman E, Harris LS, Dependence studies of new compounds in
the rhesus monkey, rat and mouse, NIDA Research Monograph,
119:519-520, 1992.
3. Broderick PA, Phelan FT, Berger SP, Ibogaine alters cocaine induced
biogenic amine and psychostimulant dysfunction but not [3H] GBR-12935
binding to the dopamine transporter protein, NIDA Research Monograph,
119:285, 1992.
4. Broderick PA, Phelan FT, Eng F, Wechsler RT, Ibogaine Modulates Cocaine
Responses Which Are Altered Due to Environmental Habituation: In Vivo
Microvoltammetric and Behavioral Studies, Pharmacology Biochemistry and
Behavior, 49(3):711-728, 1994.
5. Cappendijk SLT, Dzoljic MR, Inhibitory effects of ibogaine on cocaine
self-administration in rats, European Journal of Pharmacology,
241:261-265, 1993.
6. Cappendijk, SLT, Fekkes D, Dzoljic MR, The inhibitory effects of
norharman on morphine withdrawal syndrome in rats: comparison with
ibogaine, Behavioural Brain Research, 65:117-119, 1994.
7. Deecher DC, Teitler M, Soderland DM, Bornmann WG, Kuehne MR, Glick SD,
Mechanisms of action of ibogaine and harmaline congeners based on
radioligand binding studies, Brain Research, 571:242-247, 1992.
8. Depoortere H, Neocortical Rhythmic Slow Activity during Wakefulness and
Paradoxical Sleep in Rats, Neuropsychobiology, 18:160-168, 1987.
9. Dhahir HI, A Comparative Study of the Toxicity of Ibogaine and
Serotonin (Doctoral Dissertation, Indiana University) University
Microfilms International, 71-25-341, 1971.
10. Dzoljic ED, Kaplan CD, Dzoljic MR, Effects of Ibogaine on
Naloxone-Precepitated Withdrawal Syndrome in Chronic Morphine-Dependent
Rats, Archive of International Pharmacodynamics, 294:64-70, 1988.
11. Fernandez JW, Bwiti: An Ethnography of the Religious Imagination In
Africa, Princeton University Press, 1982.
12. Gallagher CA,Hough LB, Keefner SM, Seyed-Mozaffari A, Archer S and
Glick SD, Identification and Quantification of the Indole Alkaloid
Ibogaine in Biological Samples by Gas Chromatography-Mass Spectrometry,
Biochemical Pharmacology, 49(1):73-79, 1995.
13. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN, Effects
and aftereffects of ibogaine on morphine self-administration in rats,
European Journal of Pharmacology, 195:341-345, 1991.
14. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN, Effects of
Ibogaine on Acute Signs of Morphine Withdrawal in Rats: Independence
from Tremor, Neuropharmacology, 31(5):497-500, 1992.
15. Glick SD, Gallagher CA, Hough LB, Rossman KL, Maisonneuve IM,
Differential effects of ibogaine pretreatment on brain levels of
morphine and (+) - amphetamine, Brain Research, 588:173-176, 1992.
16. Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson E, Keller, Jr. RW,
Carlson JN, Effects of iboga alkaloids on morphine and cocaine
self-administration in rats: relationship to tremorgenic effects and
to effects on dopamine release in nucleus accumbens and striatum, Brain
Research, 657:14-22, 1994.
17a. Goutarel R, Gollnhofer O, Sillans R, Pharmacodynamics and Therapeutic
Applications of Iboga and Ibogaine, Psychedelic Monographs and Essays,
vol. 6, 1993.
17b. Goutarel R, Gollnhofer O, Sillans R, L'IBOGA CONTRE LA DEPENDENCE AUX
STUPEFIANTS. PHARMACODYNAMIE ET APPLICATIONS
PSYCHOTHERAPEAUTIQUES, Psychotropes, 3(3):63-86, 1993.
18. Harsing LG, Sershen H, Lajtha A, Evidence that ibogaine releases
dopamine from the cytoplasmic pool in isolated mouse striatum, Journal
of Neural Transmission, 96:215-225, 1994.
19. Jacobson AE, Biological Evaluation of Compounds for Their Physical
Dependence Potential and Abuse Liability. XIII. Drug Tersting Program
of the Committee on Problems of Drug Dependence, Inc., NIDA Research
Monograph, 95:563, 1990.
20. Kaplan CD, Ketzer E, de Jong J, de Vries M, Reaching a State of
Wellness: Multistage Explorations in Social Neuroscience, Social
Neuroscience Bulletin, 6(1):6-7, 1993.
21. Keefner SM, Glick SD, Ibogaine Antagonism of Morphine-Induced
Hyperactivity: Enhancement by Prior Morphine Exposure and Role of
Kappa Opioid Receptors, Society of Neuroscience Abstracts, 20:502.5,
1994.
22. Lotsof HS, U.S. patent 4,499,096; Rapid Method for Interrupting the
Narcotic Addiction Syndrome, 1985.
23. Lotsof HS, U.S. patent 4,587,243; Rapid Method for Interrupting the
Cocaine and Amphetamine Abuse Syndrome, 1986.
24. Lotsof HS, U.S. patent 4,857,523; Rapid Method for Attenuating The
Alcohol Dependency Syndrome, 1989.
25. Lotsof HS, U.S. Patent 5,026,697, Rapid Method for Interrupting or
Attenuating The Nicotine/Tobacco Dependency Syndrome., 1991.
26. Lotsof HS, U.S. patent 5,152,994; Rapid Method for Interrupting or
Attenuating Poly- drug Dependency Syndromes, 1992.
27. Lotsof HS, Ibogaine in the Treatment of Chemical Dependence
Disorders: Clinical Perspectives (A Preliminary Review), Bull. MAPS,
5(3), 1995.
28. Mash DC, Douyon R, Hearn WL, Sambol NC & Sanchez-Ramos J, A
Preliminary Report on the Safety and Pharmacokinetics of Ibogaine,
Biological Psychiatry, 1995 In Press.
29. Maisonneuve IM, Keller RW, Glick SD, Interactions between ibogaine, a
potential anti- addictive agent and morphine: an in vivo microdialysis
study, European Journal of Pharmacology, 199:35-42, 1991.
30. Maisonneuve IM, Glick SD, Interactions between ibogaine and cocaine in
rats: in vivo microdialysis and motor behavior, European Journal of
Pharmacology, 212:263- 266, 1992.
31. Maisonneuve IM, Rossman KL, Keller Jr. RW, Glick SD, Acute and
prolonged effects of ibogaine on brain dopamine metabolism and
morphine-induced locomotor activity in rats, Brain Research, 574:69-73,
1992.
32. Maisonneuve IM, Keller Jr. RW, lick, SD, Interactions of ibogaine and
D-amphetamine: in vivo microdialysis and motor behavior in rats, Brain
Research, 579:87-92, 1992.
33. Molinan HH, Maisonneuve IM, Glick SD, Dose Dependence of Ibogaine
Neurotoxicity, Society for Neuroscience Abstracts, 20:504.4, 1994.
34. Naranjo C, Psychotherapeutic Possibilities New Fantasy Enhancing
Drugs, Clinical Toxicology, 2(2):209-224, 1969.
35. Naranjo C, The Healing Journey, Pantheon Books, Div. Random House, NY,
174-228, 1973.
36. O'Hearn E, Long DB, Molliver MR, Ibogaine induces glial activation in
parasagittal zones of the cerebellum, Neuropharmacology and
Neurotoxicology, NeuroReport 4:299- 302, 1993.
37. O'Hearn E, Molliver ME, Degeneration of Purkinje Cells in Parasagittal
Zones of the
Cerebellar Vermis After Treatment with Ibogaine or Harmaline,
Neuroscience, 55(2):303-310, 1993.
38. Pearl SM, Herrick-Davis K, Teitler M, Glick SD, Radioligand-Binding
Study of Noribogaine, a Likely Metabolite of Ibogaine, Brain Research,
675, 342-344, 1995.
39. Popik P, Layer RT, Skolnick P, The Putative anti-addictive drug
ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA
receptor complex, Psychopharmacology, 114:672-674, 1994.
40. Sanchez-Ramos J, Mash DC, Ibogaine Research Update: Phase I Human
Study, MAPS, IV(4):11, 1994.
41. Schechter MD, Gordon TL, Comparison of the behavioral effects of
ibogaine from three sources: mediation of discrimintive activity,
European Journal of Pharmacology 249:70-84, 1993.
42. Schneider JA, McArthur M, Potentiation Action of Ibogaine (Bogadin TM)
on Morphine Analgesia, Experientia, XII(8):323-324, 1956.
43. Schneider JA, Sigg EB, Neuropharmacological Studies of Ibogaine, An
Indole Alkaloid with Central Stimulant Properties, Annals New York
Academy of Sciences, 66:765-776, 1957.
44. Schneider, JA, Rinehart RK, Analysis of the Cardiovascular Action of
Ibogaine Hydrochloride, Archive of International Pharmacodynamics,
CX(1):92-102, 1957.
45. Sershen H, Hashim A, Harsing L, Lajtha A, Ibogaine Antagonizes Cocaine
Induced Locomotor Stimulation in Mice, Life Sciences, 50:1079-1086,
1992.
46. Sershen H, Harsing LG, Hashim A, Lajtha A, Ibogaine Reduces
Amphetamine-Induced Locomotor Stimulation C57L/6By Mice, but Stimulates
Locomotor Activity in Rats, Life Sciences, 51:10003-1011, 1992.
47. Sershen H, Hashim A, Lajtha A, Ibogaine Reduces Preference for Cocaine
Consumption in C57BL/6By Mice, Pharmacology Biochemistry and Behavior.
46:942-948, 1993.
48. Sershen H, Hashim A, Lajtha A, Effects of Ibogaine on Serotonergic and
Dopaminergic Interactions in Striatum of Mice and Rats, Neurochemical
Research, 19(11):1463- 1465, 1994.
49. Sershen H, Hashim A, Lajtha A, The Effects of Kappa-Opioid and
5-HT3-Induced Changes in Stimulation-Evoked Dopamine Release in Vitro
from Striatum of C57BL/By Mice, Brain Research, 36(6):587-591, 1994.
50. Sharpe LG, Jaffe JH, Ibogaine Fails to Reduce Naloxone-Precipitated
Withdrawal in the Morphine-Dependent Rat, Neuropharmacology and
Neurotoxicology (NeuroReport), 1:17-19, 1990.
51. Sheppard SG, A Preliminary Investigation of Ibogaine: Case Reports and
Recommendations for Further Study, Journal of Substance Abuse
Treatment, 11(4):379-385, 1994.
52. Sisko B, Interrupting Drug Dependency with Ibogaine: A Summary of
Four Case Histories, MAPS 4(2):15-23, 1994.
53. Woods JH, Medzihdsky F, Smith CB, Winger GD, France CP, 1989 Annual
Report, Evaluation of New Compounds for Opioid Activity, NIDA Research
Monographs, 95:655-656, 1990.
